TG1050, a novel immunotherapeutic for the treatment of chronic hepatitis B, can control HBsAg and provoke HBsAg seroconversion in HBV-persistent mouse models

TG1050, a novel immunotherapeutic for the treatment of chronic hepatitis B, can control HBsAg and provoke HBsAg seroconversion in HBV-persistent mouse models

Saved in:
Bibliographic Details
Published in:Journal of clinical virology Vol. 69; p. 227
Main Authors: Lélu, K, Evlachev, A, Kratzer, R, Godon, O, Mancini-Bourgine, M, Dion, S, Schmitt, D, Dubois, C, Meritet, J.F, Schlesinger, Y, Marchand, J.B, Geist, M, Brandely, R, Findeli, A, Zhu, R, Menguy, T, Silvestre, N, Michel, M.L, Inchauspé, G, Martin, P
Format: Journal Article
Language:English
Published: Elsevier B.V 01-08-2015
Subjects:
Allergy and Immunology
Hepatitis B virus
Infectious Disease
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1386-6532
1873-5967
DOI:10.1016/j.jcv.2015.06.020